Polpharma DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News, GMP

Polpharma's HP API facility is live!

10 Oct 2024

// PRESS RELEASE

Rising Prevalence of Cancer and Its Impact on the HP API Market

10 Oct 2024

// PRESS RELEASE

Addressing Nitrosamine Risks in Pharmaceutical Manufacturing

10 Oct 2024

// PRESS RELEASE

DATA COMPILATION
#PharmaFlow

Contact Supplier

Website

DCAT Week

Attending

Book a meeting

envelop Contact Supplier

DIGITAL CONTENT

3 Interview #SpeakPharma, 11 Corporate Content #SupplierSpotlight, 2 Data Compilation #PharmaFlow, 135 News #PharmaBuzz

media
3 Interview #SpeakPharma
11 Corporate Content #SupplierSpotlight
2 Data Compilation #PharmaFlow
135 News #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

65 All APIs, 38 USDMF, 24 CEP/COS, 14 JDMF, 55 KDMF, 81 NDC API, 60 Listed APIs

65 All APIs
38 USDMF
24 CEP/COS
14 JDMF
55 KDMF
81 NDC API
60 Listed APIs

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

INTERMEDIATES

7 All Intermediates

7 All Intermediates

KEY PRODUCTS

Abemaciclib, Alendronate Sodium, Apixaban, Apremilast, Baclofen, Baricitinib, Brexpiprazole, Dapagliflozin, Dapagliflozin Propanediol Monohydrate, Empagliflozin, Enzalutamide, Hydrochlorothiazide, Isavuconazonium Sulfate, Ozanimod, Palbociclib, Pimavanserin Tartrate, Rivaroxaban, Ticagrelor, Trametinib, Vismodegib, Zoledronic Acid

SERVICES

API Manufacturing, API & Drug Product Development

pharmaServices
API Manufacturing
API & Drug Product Development
- 6 API Development

KEY SERVICES

Cryogenic Reactions, API Scale-Up, API Development Services, API Scale-Up Capabilities, HPAPI Manufacturing

Cryogenic Reactions
API Scale-Up
API Development Services
API Scale-Up Capabilities
HPAPI Manufacturing

INSPECTIONS & REGISTRATIONS

4 FDA, 54 EDQM, 1 GDUFA

inspections
4 FDA
54 EDQM
1 GDUFA

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

About

Polpharma API, part of a leading Polish pharmaceutical group, has over 70 years of experience in process development and cGMP manufacturing. We offer end-to-end solutions, from API development to scale-up, at our FDA-approved plant in Central Europe. Our expert team provides high-quality, tailor-made services for small molecule API clinical candidates, with strong regulatory support and world-class facilities. Trusted by global partners, we specialize in complex chemical processes and deliver exceptional customer experiences. Polpharma API – Your reliable European CDMO partner.

DCAT WeekDCAT Week

Industry Trade Show

Attending

17-20 March, 2025

New York, USA
World ADC LondonWorld ADC London

Industry Trade Show

Attending

03-06 March, 2025

London, UK
Ce BioForumCe BioForum

Industry Trade Show

Attending

02-03 April, 2025

Warsaw, Poland

CONTACT DETAILS

Click the arrow to open the dropdown

Country

Poland

Address

Pelplińska 19, 83-200 Starogard Gdański

Telephone

+48 585631600

api@polpharma.com

Website

https://www.api.polpharma.com/

https://www.linkedin.com/company/polpharma-api/

YouTube

https://www.youtube.com/@polpharma3506/featured

Digital content

Explore the latest content creation from this company

INTERVIEW #SpeakPharma

“Polpharma has invested over €35 million in a new facility to handle HPAPIs”

Over the recent years, the market for contract development and manufacturing organizations (CDMOs) has been growing at a fast clip owing to a plethora of factors such as the rising demand for biologics, new trends towards personalized medicines and the need to bring new treatments to the market more quickly. This week, SpeakPharma interviews Dawid Ignatowicz, Head of Key Account Management, CDMO, Polpharma, to know how the Polish drugmaker is growing its CDMO business and some of the inherent advantages it enjoys in this landscape. Of late, there has been an increase in demand for drug substance development and cGMP manufacturing services. How is Polpharma gearing up to meet this demand? In fact, the number of drug developments has increased over the past few years. This coupled with some lack of capacity in some major European CDMO’s, potentiates good opportunities for companies like Polpharma. Over the last few years, Polpharma has been growing its offer on the CDMO, either by adding new capabilities in research and development and in production or by increasing its manufacturing standards (compliance, EHS, etc.). Our objective is to support our customers into the different phases of drug development, as such we have adapted our systems to be able to answer their requirements on the different stages – with the ultimate goal of providing a reliable, efficient, and cost-effective service to the customers. What differentiates Polpharma from other CDMOs? Our major strengths can be referred as: good project management skills (we have a group of experienced people that help the customers), transparency (since the inception of a project we have developed a clear and transparent way of communicating flow with the customer so that we can have full visibility of their project in our site), an ability to listen to our customers (a rather simple requirement, but that seems difficult to find in the market), good process design (more delivery kilos of a product we want to establish a good efficient and cost-effective process) and flexibility (we understand that development projects could have changes on the timelines and the capability to adapt to those changes is critical). Besides the above, we have a positive track record of regulatory approvals coupled with experience and expertise in filing to the FDA. We have positive pre-approval inspection audits (PAIs) that reaffirm our robust quality management system. We are known for efficient management of changes and deviations — we are both open and collaborative and work alongside our clients. Tell us about the range of CDMO projects that Polpharma handles. Owing to our decades-long experience in drug substance development, regulatory filing, and commercial manufacturing, Polpharma can support customers at various phases — from clinical supplies, through validation and launch, up to regular commercial supplies. Manufacturing highly potent APIs comes with several challenges, especially with respect to toxicity and exposure. Are you observing more projects with high toxicity? In order to address the growing demand for the development and manufacture of highly active compounds, we have invested over €35 million in a new facility to handle HPAPIs that will include process and analytical R&D, small-scale cGMP manufacturing suites and quality control (QC) labs. This facility will allow us to handle compounds with an occupational exposure limit (OEL) value down to 10 ng/m3 (or OEB6, i.e. very high contamination).

Impressions: 2744

CORPORATE CONTENT #SupplierSpotlight

Product List 2025

Open PDF

Upload

Corporate Presentation

GMP Certificate 2024

CDMO Brochure 2023

Ipochem Corporate Presentation

Open PDF

Upload

Ipochem Product List 2022

Open PDF

Upload

Corporate Video

Strategic Investment in HPAPI

Polpharma Biologics - Brand Launch Video

Ideas Make It Happen

Polpharma API, Your European CDMO Partner

DATA COMPILATION #PharmaFlow

CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

The contract development and manufacturing organization (CDMO) space continued to grow at an impressive pace in the second half (H2) of 2024, with significant progress being made across cell and gene therapies (CGTs), antibody-drug conjugates (ADCs), novel drug modalities, and digital solutions.Some of the key players in the CDMO space include Lonza, EUROAPI, Evonik, SEQENS, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Axplora, PolPharma, and Famar from Europe; Mission CDMO, LGM Pharma, Veranova, and Thermo Fisher from the US; and Samsung Biologics, Bora Pharmaceuticals, and Porton Pharma Solutions from Asia. Texas-based Mission CDMO has been in the pharma industry for over 75 years. Today, it is known for its comprehensive contract services and high-quality manufacturing capabilities that have reinforced its position as a trusted partner. View CDMO Activity Tracker for H2 2024 (Free Excel Available)Bora, PolPharma drive CDMO acquisitions; Samsung Biologics clocks over US$ 4 bn in contract valueThe second half of 2024 saw several high-value acquisitions and expansions that reshaped the CDMO landscape. South Korea-based Samsung Biologics clocked a cumulative contract value of over US$ 4 billion. It signed its largest manufacturing deal with an Asia-based pharmaceutical company, valued at US$ 1.24 billion. It also announced a series of manufacturing deals with a European drugmaker worth over US$ 668 million. Samsung Biologics is also building a dedicated ADC facility that is likely to be complete soon. Taiwan’s largest CDMO, Bora Pharmaceuticals, announced its second acquisition of the year. It bought New Jersey-based Pyros Pharmaceuticals, a developer of rare disease treatments. Pyros recently launched Vigafyde, the only ready-to-use vigabatrin oral solution and the first new product approved to treat infantile spasms in 15 years. Bora also announced a strategic investment in Tanvex Biopharma, thereby creating a global platform for biologics development and supply.PolPharma acquired Ziołolek, a renowned manufacturer of dermatological products, medical devices, and OTC medicines, thereby expanding its product portfolio. It also launched a state-of-the-art HPAPI (highly potent active pharmaceutical ingredients) facility in Poland, which is being seen as another step towards securing Europe’s drug supply chain.In other developments, Avid Bioservices got acquired by funds managed by Ampersand and British healthcare investment firm GHO Capital Partners in an all-cash deal worth US$ 1.1 billion. And Agilent Technologies agreed to acquire Canadian specialty CDMO Biovectra for US$ 925 million, thereby enhancing its capabilities in gene-editing technologies and sterile fill-finish services. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Evonik, EUROAPI, Porton Pharma, GSK announce tieups, technological expansionsSeveral CDMOs announced new collaborations and acquired new capabilities to enhance their service offerings. Evonik expanded its formulation capabilities for lipid nanoparticles used for mRNA and gene therapies through a collaboration with KNAUER Wissenschaftliche Geräte. This partnership aims to expand Evonik’s portfolio of biosolutions.Evonik is also restructuring its keto and pharma amino acid business to focus on strategic core growth areas. Evonik launched Eudracap colon functional capsules for targeted delivery of oral drugs. These ready-to-fill capsules are designed to release their contents specifically in the colon, improving the efficacy of treatments for various gastrointestinal conditions. Evonik also opened a new facility for drying aqueous dispersions of Eudragit polymers in Darmstadt, Germany. This facility will enhance Evonik’s capabilities in producing high-quality polymers for pharmaceutical applications.EUROAPI launched a new AI-powered Electronic Batch Record solution in collaboration with Aizon to enhance manufacturing productivity. This collaboration aims to digitize operations towards more data-driven manufacturing, focusing on small-scale productions and highly flexible plants.Porton Pharma Solutions has expanded its reach through several strategic initiatives. In October, Porton entered into a partnership with Shanghai InnoStar to enhance its service offerings beyond small molecules, targeting peptides, oligonucleotide drugs, conjugated drugs, and advanced therapies. It continued to grow its capabilities by enhancing its GMP manufacturing capacity in Fengxian, Shanghai (China). The facility’s expansion is aimed at increasing the production of novel therapies, including peptides and oligonucleotide drugs. These moves are part of Porton’s broader strategy to position itself at the forefront of advanced pharmaceutical manufacturing.Corden Pharma is investing € 900 million (US$ 985 million) over the next three years to expand its peptide platform facilities in Colorado (US) and Europe. While the US site will help meet the rising demand for GLP-1 peptides, in Europe, CordenPharma will construct a greenfield facility for small to large-scale peptide development and manufacturing.CDMO Touchlight signed a licensing agreement with GSK that grants the drug behemoth non-exclusive rights to use Touchlight’s proprietary enzymatic doggybone DNA (dbDNA) technology for the development and production of mRNA-based products, particularly vaccines. Curia also integrated enzymatic dbDNA solutions through a collaboration with Touchlight, enhancing mRNA production for vaccine and cancer therapies. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Lonza, Merck, Dr. Reddy’s owned Aurigene invest in cell and gene therapiesThe CGT space continued to draw both deals and investments. Lonza and Vertex signed a long-term commercial supply agreement for Casgevy, the world’s first CRISPR/Cas9 gene-edited cell therapy, to treat sickle cell disease and beta thalassemia. This agreement includes manufacturing at Lonza’s Geleen (the Netherlands) cell therapy manufacturing facility, with plans to expand to Portsmouth, New Hampshire (US).Miltenyi Biotec began manufacturing lentiviral vectors for Adaptimmune’s Tecelra, the first engineered TCR T-cell therapy for the rare soft tissue cancer synovial sarcoma approved by the US Food and Drug Administration.Merck KGaA commenced commercial production at its first GMP-compliant manufacturing line for cell culture media (CCM) in China. This facility addresses the growing local demand for quality custom CCM used in biopharmaceuticals, vaccines, and novel therapeutics.Aurigene and Edity Therapeutics announced a strategic collaboration in cell therapy, with Aurigene providing cell therapy discovery services to support Edity’s clinical development. Additionally, Aurigene and its parent, Dr. Reddy’s Laboratories, signed a memorandum of understanding (MoU) with Kainomyx for the development and commercialization of an affordable anti-malarial drug. ProBio and UCI Therapeutics signed an MoU for a comprehensive collaboration in gene delivery technologies, including viral and non-viral approaches. Additionally, Korea’s VaxCell-Bio partnered with ProBio to accelerate the development of its chimeric antigen receptor (CAR)-related therapies.The ADC market continued to be a hotbed of innovation and strategic expansion. Merck KGaA invested € 70 million (US$ 75 million) to triple its ADC manufacturing capacity at its Missouri (US) facility, aiming to support the rising demand for oncology therapies.Sterling Pharma entered into a partnership with GlycoNex to support the clinical trials of their ADCs that target solid tumors. And, NJ Bio and Charles River Laboratories also announced a collaboration to optimize ADC manufacturing.The adeno-associated viral (AAV) vector field also saw activity with Rentschler Biopharma and Forge Biologics announcing the launch of a new service offering and a manufacturing platform, respectively. Similarly, Andelyn Biosciences was selected by Hubble Therapeutics to manufacture clinical grade AAV.Meanwhile, Lonza has gone in for a restructuring exercise in order to become a “pure-play CDMO”. It has exited its capsules and health ingredients business, and adopted a new organizational structure. The Swiss CDMO has also extended a collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Our viewAs pharmaceutical development becomes increasingly complex, CDMOs are no longer just manufacturing partners, but critical innovation hubs. Little wonder then that 2024’s biggest pharma deal was in the CDMO space – Novo Holdings’ US$ 16.5 billion buyout of Catalent. This trend should gather momentum. We expect more M&A activity in this space in 2025.

Impressions: 2525

FDA approves record eight biosimilars in H1 2024; okays first interchangeable biosimilars for Eylea

Biologics, or complex drugs that are derived from living organisms, have revolutionized treatment of various conditions such as cancer, autoimmune diseases, and chronic illnesses. In 2023, eight out of 10 of the world’s top-selling drugs were biologics, including Merck’s Keytruda, AbbVie’s Humira, and Sanofi’s Dupixent.Due to their high costs, accessibility of biologics has been a challenge. That’s why biosimilars, or game-changing copycats of biologics that provide highly similar yet more affordable alternatives to established biologics, are becoming popular.The first biosimilar — Sandoz’ Zarxio — was approved by the US Food and Drug Administration (FDA) in 2015. Its reference biologic was Amgen’s Neupogen (filgrastim). Since then, the global market for biosimilars has been growing at an impressive pace — between 2015 and 2020, it grew at a whopping compounded annual growth rate (CAGR) of 78 percent, touching US$ 17.9 billion in size. It is expected to continue growing at a CAGR of 15 percent and reach a size of about US$ 75 billion by 2030.Major biosimilar players include Amgen, Sandoz, Samsung Bioepis, Pfizer, Biocon Biologics, Celltrion, Stada Arzneimittel, Accord Healthcare, Fresenius Kabi, Coherus Biosciences, Apotex, and Sanofi. The increasing demand for biosimilars has propelled growth in contract manufacturing. Some of the leading contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) that manufacture biosimilars are Polpharma Biologics, Catalent, Pfizer CentreOne, Lonza, Boehringer Ingelheim BioXcellence, Thermo Fisher Scientific, WuXi Biologics, and FUJIFILM Diosynth Biotechnologies.Access the Interactive Dashboard for Biosimilar Developments (Free Excel)Amgen, Sandoz top list of ‘approved biosimilars’; FDA okays 8 copycats in H1 2024Over the recent years, regulatory agencies like the FDA and the European Medicines Agency (EMA) have established rigorous approval pathways for biosimilars.Since 2015, FDA has approved 53 biosimilars, while the EMA has approved 86 biosimilars. Among the US, European and Canadian markets, Amgen and Sandoz are tied in the first place with 13 approved biosimilars each. Samsung Biologics has nine approved biosimilars, followed by Pfizer with eight and Biocon Biologics with seven. In the first half of this year, FDA set a record by approving eight biosimilars — the highest for H1 of any year. EMA has okayed six biosimilars so far in 2024.In 2023, five biosimilars were approved by the FDA with just one being okayed in the first half. The year marked the end of exclusivity for Humira after 20 years, in which it netted a total of US$ 200 billion in sales. AbbVie’s flagship autoimmune drug has a record 10 biosimilars.Johnson & Johnson’s Stelara also lost exclusivity in 2023 and as many as 11 drugmakers hope to bring its biosimilars to the market. Amgen’s Wezlana was the first biosimilar to Stelara, and it was approved as interchangeable by FDA in October last year.Access the Interactive Dashboard for Biosimilar Developments (Free Excel) FDA approves first interchangeable biosimilar for Eylea, cuts regulatory feeDeveloping a biosimilar costs both money and time. According to Pfizer, developing a biosimilar can take five to nine years and cost over US$ 100 million, not including regulatory fees.In October 2023, FDA slashed its fees with the program fee at US$ 177,397, down from US$ 304,162. The application fees for products that require clinical data has been set at US$ 1,018,753, down from US$ 1,746,745. The application fee for products that don’t require clinical data has been set lower — at US$ 509,377 — down from US$ 873,373 set earlier. This reduction in application fee has propelled demand for contract manufacturing of biosimilars.There has also been a rise in approvals of interchangeable biosimilars this year. Interchangeable biosimilars meet additional requirements and may be substituted for its reference product by a pharmacist without consulting the prescriber. This year saw FDA approve the first interchangeable biosimilars for bone cancer drug denosumab (Prolia and Xgeva) in Jubbonti and Wyost as well as for eculizumab (Soliris) in Bkemv.In May, FDA approved the first interchangeable biosimilars for eye drug aflibercept (Eylea) in Opuviz and Yesafili. Other biosimilars approved in 2024 include Simlandi for adalimumab (Humira), Tyenne for tocilizumab (Actemra), Selarsdi for ustekinumab (Stelara), and Hercessi for trastuzumab (Herceptin).Access the Interactive Dashboard for Biosimilar Developments (Free Excel) Merck’s Keytruda, BMS’ Opdivo, Novartis’ Cosentyx brace for biosimilar competitionHealthcare spending in the US is projected to rise from US$ 4.5 trillion in 2022 to US$ 6 trillion by 2027. While biologics involve just two percent of prescriptions, they account for 46 percent of all pharmaceutical spending. In 2022, US$ 252 billion was spent on biologics.Biosimilar-related savings in 2023 were estimated to be US$ 9.4 billion in the US and € 10 billion (US$ 10.68 billion) in Europe. With expensive and widely used drugs like AbbVie’s Humira, J&J’s Stelara, and Regeneron’s Eylea coming under competition, US savings are projected to reach US$ 181 billion through 2027. Between 2026 and 2032, about 39 blockbusters are set to lose exclusivity in the US and Europe. Merck’s Keytruda (pembrolizumab) was the world’s top-selling drug last year, generating US$ 25 billion in sales. Its patent is set to expire in 2028 with sales expected to drop 19 percent to US$ 27.4 billion in 2029 from US$ 33.7 billion the previous year. Samsung Bioepis and Amgen initiated phase 3 trials of pembrolizumab in April and May of this year, respectively.Opdivo (nivolumab), belonging to the same class of drugs, competes with Keytruda and is also set to lose patent protection in 2028. It hauled in US$ 10 billion in total global sales in 2023 for Bristol Myers Squibb. The key patents of Novartis’ Cosentyx (secukinumab) are set to expire between 2025 and 2026. Cosentyx saw sales of US$ 5 billion in 2023. Taizhou Mabtech Pharmaceutical and Bio-Thera Solutions are conducting phase 3 trials of secukinumab.Access the Interactive Dashboard for Biosimilar Developments (Free Excel) Our viewWith over 2 billion people worldwide unable to access life-saving medicines, biosimilars hold the key to healthcare accessibility. In 2023, a record 13 biosimilars were launched in the market — the highest for a single year. And this included nine much-anticipated biosimilars to AbbVie’s Humira. In April this year, FDA announced a Biosimilars Action Plan to streamline the development of biosimilars. With a sharp focus on biosimilars, we expect more records to be broken in the near term. New launches of biosimilars to drugs like J&J’s Stelara, Regeneron’s Eylea and Merck’s Keytruda will surely help in creating new records.

Impressions: 2708

NEWS #PharmaBuzz

Polpharma's HP API facility is live!

10 Oct 2024

// PRESS RELEASE

Rising Prevalence of Cancer and Its Impact on the HP API Market

10 Oct 2024

// PRESS RELEASE

Addressing Nitrosamine Risks in Pharmaceutical Manufacturing

10 Oct 2024

// PRESS RELEASE

Polpharma acquires Ziołolek

01 Oct 2024

// PRESS RELEASE

Polpharma & MSN Lab Announce Strategic Distribution Partnership

23 Sep 2024

// PRESS RELEASE

Polpharma’s strategic investment in HPAPI facility, the first of this kind in Poland

12 Sep 2024

// PRESS RELEASE

ALL APIs

Click the button for full data set

01

Acetazolamide

Poland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

USDMF

Click Us!

CEP/COS

JDMF

EU-WC NDC

KDMF

VMF ASMF

AUDIT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

02

Alendronate Sodium

Poland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

USDMF

CEP/COS

JDMF

EU-WC NDC

KDMF

VMF ASMF, CA

AUDIT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

03

Etodolac

Poland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

USDMF

CEP/COS

JDMF

EU-WC NDC KDMF

VMF ASMF, CA

AUDIT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

04

Hydrochlorothiazide

Poland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

USDMF

CEP/COS

JDMF

EU-WC NDC

KDMF

VMF ASMF, CN...

AUDIT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

05

Ibandronate Sodium

Poland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

USDMF

CEP/COS

JDMF

EU-WC NDC KDMF

VMF Others AUDIT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

06

Lamotrigine

Poland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

USDMF

CEP/COS

JDMF

EU-WC NDC KDMF

VMF ASMF, CN

AUDIT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

07

Risedronate Sodium

Poland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

USDMF

CEP/COS

JDMF

EU-WC NDC

KDMF

VMF ASMF, CA

AUDIT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

08

Sildenafil Citrate

Poland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

USDMF

CEP/COS

JDMF

EU-WC NDC

KDMF VMF ASMF, CN...

AUDIT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

09

Tadalafil

Poland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

USDMF

CEP/COS

JDMF

EU-WC NDC KDMF VMF ASMF, CN

AUDIT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

10

Vardenafil Hydrochloride

Poland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

USDMF

CEP/COS

JDMF

EU-WC NDC

KDMF

VMF ASMF, CN...

AUDIT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

CEP/COS

01

Acetazolamide

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

Certificate Numbers : R1-CEP 2010-371 - Rev 02

Status : Valid

Issue Date : 2020-08-04

Type : Chemical

Substance Number : 454

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

02

Aripiprazole

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

Certificate Numbers : R1-CEP 2013-230 - Rev 02

Status : Valid

Issue Date : 2023-03-17

Type : Chemical

Substance Number : 2617

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

03

Carbamazepine, Crystallised in ethanol

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

Certificate Numbers : R1-CEP 2012-353 - Rev 01

Status : Valid

Issue Date : 2021-01-21

Type : Chemical

Substance Number : 543

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

04

Carbamazepine, standard, milled, microni...

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

Certificate Numbers : CEP 2004-141 - Rev 04

Status : Valid

Issue Date : 2024-12-02

Type : Chemical

Substance Number : 543

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

05

Carvedilol

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

Certificate Numbers : R1-CEP 2002-258 - Rev 08

Status : Valid

Issue Date : 2021-10-22

Type : Chemical

Substance Number : 1745

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

06

Etodolac, Micronised, non-micronised

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

Certificate Numbers : CEP 2013-134 - Rev 03

Status : Valid

Issue Date : 2024-12-02

Type : Chemical

Substance Number : 1422

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

07

Hydrochlorothiazide, Standard grade, mic...

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

Certificate Numbers : CEP 2004-058 - Rev 06

Status : Valid

Issue Date : 2024-04-12

Type : Chemical

Substance Number : 394

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

08

Ibandronate sodium monohydrate

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

Certificate Numbers : R0-CEP 2022-073 - Rev 00

Status : Valid

Issue Date : 2023-02-20

Type : Chemical

Substance Number : 2771

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

09

Ibandronate sodium monohydrate, Type I

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

Certificate Numbers : R0-CEP 2023-077 - Rev 00

Status : Valid

Issue Date : 2023-06-30

Type : Chemical

Substance Number : 2771

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

10

Lamotrigine

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

Certificate Numbers : R1-CEP 2010-128 - Rev 02

Status : Valid

Issue Date : 2023-02-16

Type : Chemical

Substance Number : 1756

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

01

Acetazolamide

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

Registrant Name : Wooshin Labotech Co., Ltd.

Registration Date : 2020-10-19

Registration Number : 20201019-210-J-595

Manufacturer Name : Pharmaceutical Works Polpharma...

Manufacturer Address : 19. Pelplinska Str, 83-200 Starogard Gdanski, Poland

Product
Web Link

Stock Recap
#Pipeline Prospector

Market
Place

02

alendronate sodium hydrate

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

Registrant Name : Hwail Pharmaceutical Co., Ltd.

Registration Date : 2018-10-23

Registration Number : 20181023-209-J-116

Manufacturer Name : Pharmaceutical Works Polpharma...

Manufacturer Address : 19, Pelplinska Str. 83-200 Starogard Gdanski, Poland

Product
Web Link

Stock Recap
#Pipeline Prospector

Market
Place

03

alendronate sodium hydrate

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

Registrant Name : Korea United Pharmaceutical Co., Ltd.

Registration Date : 2019-08-29

Registration Number : 20181023-209-J-116(2)

Manufacturer Name : Pharmaceutical Works Polpharma...

Manufacturer Address : 19. Pelplinska Str, 83-200 Starogard Gdanski, Poland

Product
Web Link

Stock Recap
#Pipeline Prospector

Market
Place

04

alendronate sodium hydrate

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

Registrant Name : Daewon Pharmaceutical Co., Ltd.

Registration Date : 2021-04-27

Registration Number : 20181023-209-J-116(3)

Manufacturer Name : Pharmaceutical Works Polpharma...

Manufacturer Address : 19, Pelplinska Street., 83-200 Starogard Gdanski, Poland

Product
Web Link

Stock Recap
#Pipeline Prospector

Market
Place

05

alendronate sodium hydrate

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

Registrant Name : Wooshin Labotech Co., Ltd.

Registration Date : 2019-08-02

Registration Number : 20181023-209-J-116(1)

Manufacturer Name : Pharmaceutical Works Polpharma...

Manufacturer Address : 19. Pelplinska Str, 83-200 Starogard Gdanski, Poland

Product
Web Link

Stock Recap
#Pipeline Prospector

Market
Place

06

alendronate sodium hydrate

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

Registrant Name : Pami Future Co., Ltd.

Registration Date : 2022-04-18

Registration Number : 20181023-209-J-116(4)

Manufacturer Name : Pharmaceutical Works Polpharma...

Manufacturer Address : 19. Pelplinska Str, 83-200 Starogard Gdanski, Poland

Product
Web Link

Stock Recap
#Pipeline Prospector

Market
Place

07

Apixaban

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

Registrant Name : Wooshin Labotech Co., Ltd.

Registration Date : 2020-09-04

Registration Number : No. 172-5-ND(1)

Manufacturer Name : Pharmaceutical Works Polpharma...

Manufacturer Address : 19. Pelplinska Str, 83-200 Starogard Gdanski, Poland

Product
Web Link

Stock Recap
#Pipeline Prospector

Market
Place

08

Apixaban

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

Registrant Name : IMCD Korea Co., Ltd.

Registration Date : 2020-08-05

Registration Number : Su172-5-ND

Manufacturer Name : Zakłady Farmaceutyczne Polpha...

Manufacturer Address : ul. Peplińska 19, 83-200 Starogard Gdański, POLAND

Product
Web Link

Stock Recap
#Pipeline Prospector

Market
Place

09

Baclofen

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

Registrant Name : Wooshin Labotech Co., Ltd.

Registration Date : 2019-08-02

Registration Number : 20181018-209-J-161(5)

Manufacturer Name : Pharmaceutical Works Polpharma...

Manufacturer Address : 19, Pelplinska Street. 83-200 Starogard Gdanski, Poland

Product
Web Link

Stock Recap
#Pipeline Prospector

Market
Place

10

Baclofen

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

Registrant Name : Korea United Pharmaceutical Co., Ltd.

Registration Date : 2019-01-24

Registration Number : 20181018-209-J-161(3)

Manufacturer Name : Pharmaceutical Works Polpharma...

Manufacturer Address : 19, Pelplinska Str.83-200 Starogard Gdanski, Poland

Product
Web Link

Stock Recap
#Pipeline Prospector

Market
Place

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

01

ACETAZOLAMIDE

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

NDC Package Code : 12658-0359

Start Marketing Date : 1982-01-01

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (40kg/40kg)

Marketing Category : BULK INGREDIENT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

02

ACETAZOLAMIDE

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

NDC Package Code : 12658-0471

Start Marketing Date : 1982-01-01

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (31kg/31kg)

Marketing Category : BULK INGREDIENT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

03

ACETAZOLAMIDE

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

NDC Package Code : 12658-0468

Start Marketing Date : 1982-01-01

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (21kg/21kg)

Marketing Category : BULK INGREDIENT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

04

ACETAZOLAMIDE

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

NDC Package Code : 12658-0460

Start Marketing Date : 1982-01-01

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (34kg/34kg)

Marketing Category : BULK INGREDIENT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

05

ACETAZOLAMIDE

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

NDC Package Code : 12658-0466

Start Marketing Date : 1982-01-01

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (10kg/10kg)

Marketing Category : BULK INGREDIENT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

06

ACETAZOLAMIDE

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

NDC Package Code : 12658-0457

Start Marketing Date : 1982-01-01

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (4kg/4kg)

Marketing Category : BULK INGREDIENT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

07

ACETAZOLAMIDE

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

NDC Package Code : 12658-0465

Start Marketing Date : 1982-01-01

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (3kg/3kg)

Marketing Category : BULK INGREDIENT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

08

ACETAZOLAMIDE

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

NDC Package Code : 12658-0453

Start Marketing Date : 1982-01-01

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (36kg/36kg)

Marketing Category : BULK INGREDIENT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

09

ACETAZOLAMIDE

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

NDC Package Code : 12658-0475

Start Marketing Date : 1982-01-01

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (30kg/30kg)

Marketing Category : BULK INGREDIENT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

10

ACETAZOLAMIDE

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Polpharma

NDC Package Code : 12658-0438

Start Marketing Date : 1982-01-01

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (25kg/25kg)

Marketing Category : BULK INGREDIENT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

Only 10 entries up to this point, click to access all

LISTED APIs

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

01 Polpharma

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Lead Product(s) : Flaxseed

Therapeutic Area : Dermatology

Highest Development Status : Approved

Recipient : Ziololek

Deal Size : Undisclosed

Deal Type : Acquisition

DEALS_DEV

Polpharma Acquires Ziołolek

Details : Through the acquisition, Polpharma enhanced its portfolio of OTC & dermatology products, including Linomag (linseed oil), which is indicated for treating skin conditions such as eczema & intertrigo.

Product Name : Linomag

Product Type : Small molecule

Upfront Cash : Undisclosed

October 01, 2024

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

02 Polpharma

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Lead Product(s) : RVU120

Therapeutic Area : Oncology

Highest Development Status : Preclinical

Partner/Sponsor/Collaborator : Ryvu Therapeutics

Deal Size : $1.0 million

Deal Type : Agreement

DEALS_DEV

Ryvu Therapeutics Enters into Two Agreements with Zakłady Farmaceutyczne Polpharma S.A. in the Ar...

Details : RVU120 is a selective, first-in-class dual CDK8/CDK19 kinase inhibitor that has shown signs of clinical activity in treated patients, as well as efficacy in numerous in vitro and in vivo models of hematologic malignancies and solid tumors.

Product Name : RVU120

Product Type : Small molecule

Upfront Cash : Undisclosed

July 06, 2023

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

03 Polpharma

Poland

DCAT Week

Attending

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Lead Product(s) : PKL-021

Therapeutic Area : Neurology

Highest Development Status : Preclinical

Partner/Sponsor/Collaborator : Pikralida biopharmaceutical

Deal Size : Undisclosed

Deal Type : Partnership

DEALS_DEV

Polpharma Partners with Pikralida Biopharmaceutical Start-Up

Details : The partnership involves manufacturing of the drug substance of the clinical candidate PKL-021, needed to support the preclinical research program and the production of an investigational medicinal product for the phase one clinical trial.